SOHC
SWISS ONCOLOGY & HEMATOLOGY CONGRESS

AL-Amyloidosis: Comprehensive Screening and Monitoring (COSMO-AL) - An exploratory prospective study

Max J. Rieger[1], Giorgia Melli[2], Hans Jung[3], Andreas Flammer[4], Rahel Schwotzer[1]

[1]Department of Medical Oncology and Hematology, USZ [2]Neurocenter of Southern Switzerland, [4]Department of Neurology, USZ, [4]Heart Center Zurich, USZ

USZ Universitäts Spital Zürich

University of Zurich[UZH]







Background

- sALA presumably underdiagnosed in Myeloma (estimate: up to 20%)
- PNS: overlooked site of deposition / est. screening methods invasive
- Serum neurofilament light chains (sNFL): **biomarker** of PNS damage
- Random skin biopsies with nerve fiber density measurements: less invasive method for **detection of Amyloid and PNS rarefication**

Goals

- **MGCS/Myeloma**: Improve screening of sALA + PNS affection
- **sALA**: Confirm sNFL as activity + response parameter in sALA



- ➢ sNFL higher in sALA
- ➢ Total 41 screened (5 pos.) with skin biopsy; N= 3/5 with otherwise undetected amyloidosis

Presented at SOHC 2025 from 19 – 21 November 2025